Serum IncRNA LOXL1-AS1 is a diagnostic and prognostic marker for epithelial ovarian cancer

Chun-Na Liu1 | Hai-Yan Zhang2

1Department of Gynecology, Linyi Cancer Hospital, Linyi, Shandong, China
2Clinical Laboratory, Linyi Cancer Hospital, Linyi, Shandong, China

Abstract

Background: The present study aimed to examine the levels of circulating LOXL1-AS1 in epithelial ovarian cancer (EOC) patients and to analyze its diagnostic and prognostic value.

Methods: The levels of LOXL1-AS1 in 185 EOC patients and 43 healthy volunteers were evaluated by a quantitative reverse transcriptase-polymerase chain reaction. The potential of LOXL1-AS1 as a biomarker for EOC diagnosis was determined by receiver-operating characteristic (ROC) curve assays. The associations between clinicopathological parameters and LOXL1-AS1 expression were analyzed using a chi-squared test. The influence of LOXL1-AS1 on overall survival was analyzed by the use of Kaplan–Meier. A Cox proportional hazards assays were conducted for the determination of the prognostic value of LOXL1-AS1.

Results: The expression of LOXL1-AS1 was dramatically higher in EOC patients compared to healthy controls ($p < 0.01$). LOXL1-AS1 yielded an area under the ROC curve of 0.843 with 65.3% sensitivity and 68.2% specificity in discriminating high-grade EOC from healthy controls. It was also shown that LOXL1-AS1 expression was associated with advanced FIGO stage ($p = 0.004$) and positively distant metastasis ($p = 0.013$). Kaplan–Meier assays revealed that patients with high LOXL1-AS1 expression had a shorter overall survival than those with low expression ($p = 0.0006$). By performing multivariate assays, LOXL1-AS1 was confirmed to be an independent prognostic factor for predicting the prognosis of EOC patients.

Conclusions: We provide evidence indicating that LOXL1-AS1 expression is correlated with a poor clinical outcome in EOC patients and may act as an independent prognostic indicator, as well as a new diagnostic biomarker.

Keywords: circulating LOXL1-AS1, diagnosis, EOC, IncRNA, prognosis

1 INTRODUCTION

Epithelial ovarian cancer (EOC) remains one of the most prevalent and destructive gynecological neoplasms with an increased incidence in China.$^{1,2}$ EOC is classified into four histologic grades in agreement with World Health Organization (WHO) criteria.$^3$ Despite the clinical application of the effective treatment approaches for EOC, including surgery, radiotherapy and chemotherapy, the average survival of patients with
this tumor has improved only slightly.\textsuperscript{4,5} Thus, it is always of great interest to identify novel and efficient cancer biomarkers for use in the diagnosis and prediction of prognosis for EOC patients.

It has been confirmed that the majority of human transcripts are non-coding RNAs (ncRNAs) initially considered to represent spurious transcriptional noise.\textsuperscript{6} Long non-coding RNAs (lncRNAs) comprise a class of ncRNAs that are greater than 200 nucleotides in length and lack the potential of coding proteins.\textsuperscript{7} Growing studies in recent years have shown that lncRNAs play a critical role in the modulation of a series of cellular processes in the shape of RNAs and display less evolutionary constraint.\textsuperscript{8,9} In addition, lncRNAs are also reported to be involved in gene regulation at different levels, especially epigenetic modification.\textsuperscript{10} Interestingly, in cancer research, lncRNAs are confirmed to act as tumor suppressors or oncopgenes in the progression of tumors.\textsuperscript{11,12} Furthermore, the dysregulation of various lncRNAs has been documented in EOC, which has promoted growing interest in their potential as prognostic and diagnostic biomarkers.\textsuperscript{13,14} Meanwhile, further reports assessing the involvement of IncRNA in EOC are scarce.

lncRNA LOXL1-antisenseRNA (LOXL1-AS1) is located on chromosome 15q24.1 and is approximately 480 nucleotides in size.\textsuperscript{15} Previously, LOXL1-AS1 was reported to be a tumor promoter of glioblastoma and was also shown to be expressed abnormally in prostate cancer.\textsuperscript{16,17} However, the clinical impact of LOXL1-AS1 in EOC has remained largely unclear. In the present study, we aimed to investigate the expression profiles of circulating LOXL1-AS1 and its diagnostic and prognostic value in EOC patients.

## 2 | MATERIALS AND METHODS

### 2.1 | Patients and specimens

In total, 43 healthy volunteers and 185 EOC patients were enrolled from Linyi Cancer Hospital between December 2011 and May 2014. The ages of all the patients ranged from 29 to 68 years, with an average age of 51 years. No radiotherapy or chemotherapy was received before surgery for all EOC patients. The follow-up information on these cases was also integrated. The clinical parameters of EOC patients in this study are presented in Table 1. Ethical approval was obtained from the Ethics Committee of Linyi Cancer Hospital, and every subject provided their written informed consent before surgery.

### 2.2 | Collection of samples

Blood samples from all subjects were collected in gel separator tubes (TransGen Biotech, Haidian, Beijing, China). After the collection of blood samples, centrifuging was used to separate the plasma and surplus elements at 1200 g for 30 minutes. Then, separate components were stored in 1.5-mL RNase free tubes (TransGen Biotech) at −80°C for further reverse transcriptase-polymerase chain reaction (RT-PCR) assays.

### 2.3 | Quantitative qRT-PCR

Total RNAs were extracted from 600 mL of plasma from all samples using Trizol Reagent (Ambion, Pudong, Shanghai, China). The concentration and purity of total RNA were examined using a NanoDrop ND-1000 spectrometer (NanoDrop Technologies, Haidian, Beijing, China). First-strand cDNA was synthesized using Reverse EasyScript One Step gDNA Removal and cDNA Synthesis SuperMix (Xinghan Tech, Pudong, Shanghai, China). Next, RT-PCR was carried out by manipulating a SYBR Premix Ex Taq II (TaKaRa, Otsu, Shiga, Japan) on a CFX96 real-time PCR Systems (TaKaRa, Otsu, Shiga, Japan). The amplification of PCR was started with 10 minutes of denaturation at 95°C, followed by 50 amplification cycles (12 seconds at 95°C, 20 seconds at 60°C and 10 seconds at 72°C). These data were further analyzed employing the comparative Ct methods with GAPDH as the endogenous control for the normalization of experimental data. The PCR primers for LOXL1-AS1 or GAPDH were designed as: LOXL1-AS1 forward, 5'-TTCCCATTTACCTGCCCGAAG-3' and reverse, 5'-GTCAGCAAACACATGGCAAC-3'; GAPDH forward, 5'-CAATGACCCCTTCATTGACC-3' and reverse, 5'-GACAAGCTTCCCGTTCTCAG-3'.

### 2.4 | Statistical analysis

All statistical analyses were performed using SPSS, version 18.0 (SPSS Inc., Chicago, IL, USA) or Prism, version 5.0 (GraphPad Software Inc., La Jolla, CA, USA). Statistical differences were examined using Student’s t test. The diagnostic value of circulating LOXL1-AS1 for EOC was examined by calculating the area under the receiver-operating characteristic (ROC) curve (AUC). A chi-squared test was performed to determine

| Variable         | Number | Circulating LOXL1-AS1 expression | p value |
|------------------|--------|----------------------------------|---------|
| age (years)      |        |                                  |         |
| < 50             | 116    | High 62                          | 0.190   |
| ≥ 50             | 69     | Low 30                           |         |
| Tumor size (cm)  |        |                                  |         |
| ≤ 8              | 119    | High 64                          | 0.139   |
| > 8              | 66     | Low 28                           |         |
| Ascites          |        |                                  |         |
| <100             | 73     | Low 40                           | 0.266   |
| ≥100             | 112    | High 52                          |         |
| FIGO stage       |        |                                  |         |
| I + II           | 118    | High 68                          | 0.004   |
| III + IV         | 67     | Low 24                           |         |
| Distant metastasis |      |                                  | 0.013   |
| Yes              | 127    | Low 71                           |         |
| No               | 58     | High 21                          |         |
correlations between LOXL1-AS1 overexpression and clinicopathologic variables of the EOC samples. Survival curves were constructed with the Kaplan–Meier methods and compared by log-rank tests. The prognostic impact of survival variables was evaluated using a multivariate analysis. \( p < 0.05 \) was considered statistically significant.

### 3 RESULTS

#### 3.1 Circulating LOXL1-AS1 expression is up-regulated in EOC tissues

To study the specific function of circulating LOXL1-AS1 in EOC patients, the expression pattern of circulating LOXL1-AS1 in EOC patients and healthy volunteers was detected with qRT-PCR. As shown in Figure 1A, it was found that the expression of circulating LOXL1-AS1 was distinctly higher in EOC patients compared to healthy controls \( (p < 0.01) \). In addition, we also found that patients with advanced stages displayed a higher expression of LOXL1-AS1 (Figure 1B). Overall, our findings revealed that dysregulation of LOXL1-AS1 may participate in the pathogenesis of hepatocellular carcinoma.

#### 3.2 The diagnostic value of circulating LOXL1-AS1 in EOC patients

We next explored the diagnostic value of circulating LOXL1-AS1 in EOC patients using ROC analysis. As shown in Figure 2, the results showed that circulating LOXL1-AS1 effectively differentiated primary EOC patients from normal controls with an AUC of 0.843 (95% confidence interval [CI] = 0.756–0.931; \( p < 0.001 \)). At the optimal cut-off value of 4.52 for circulating LOXL1-AS1, the sensitivity was 63.7% and the specificity was 85.3%, with an AUC of 0.745 with respect to distinguishing EOC patients from healthy individuals. However, when we explored the diagnostic value of circulating LOXL1-AS1 with respect to distinguishing low-grade patients from healthy individuals, the diagnostic effects were limited. Thus, our findings suggested that the detection of circulating LOXL1-AS1 may help with the diagnosis of EOC patients.

#### 3.3 Relationship between clinicopathological factors and circulating LOXL1-AS1 expression in EOC patients

To further analyze the clinical significance of circulating LOXL1-AS1 in clinical progression of EOC, all subjects were classified into a high expression group \( (n = 93) \) and a low expression group \( (n = 92) \). The relationships between circulating LOXL1-AS1 expression levels and clinical parameters are presented in Table 1. We found that a high circulating LOXL1-AS1 level was remarkably correlated with advanced FIGO stage \( (p = 0.004) \) and positively distant metastasis \( (p = 0.013) \) (Table 1). However, no significant correlations between circulating LOXL1-AS1 expression and other parameters were observed, such as gender, age and tumor size (all \( p > 0.05 \)).

#### 3.4 Circulating LOXL1-AS1 expression is an independent predictor for overall survival

Moreover, Kaplan–Meier assays were conducted to detect the prognostic value of LOXL1-AS1 in EOC patients. As shown in Figure 3, it was observed that the 5-year overall survival of high-circulating
LOXL1-AS1 group (85.9%) was distinctly lower than that of low-circulating LOXL1-AS1 group (62.4%; \( p = 0.006 \)). Furthermore, in the univariate Cox model, we showed that FIGO stage, distant metastasis and circulating LOXL1-AS1 expression were correlated with the survival rate of EOC patients (All \( p > 0.05 \)) (Table 2). More importantly, using multivariate Cox regression analyses, our group demonstrated that circulating LOXL1-AS1 expression could be regarded as an independent predictor with respect to predicting the prognosis of EOC patients (relative risk = 3.053, 95% CI = 1.154–4.784, \( p = 0.007 \)), in addition to FIGO stage and WHO grade (Table 2).

4 | DISCUSSION

EOC is the most common gynecological tumors in women worldwide. Despite the safe surgical resection followed by adjuvant chemotherapy and radiotherapy, the long-term overall survival remains short. The lack of effective methods for the detection of EOC early is one of the major factors contributing to the high mortality in patients with EOC.\(^{18,19}\) Thus, the identification of useful biomarkers for the screening of patients with EOC might result in a significant improvements in their survival rates. Previously, IncRNAs were reported to be dysregulated in EOC and to be involved in the metastasis of tumor cells, suggesting that IncRNAs may be used as potential biomarkers. In addition, several studies have focused on identifying circulating IncRNAs as cancer biomarkers in serum or plasma.\(^{20}\) Importantly, several important IncRNAs such as IncRNA MALAT1 and IncRNA HIF1A-AS1 were identified as candidates in the exploration of novel biomarkers.\(^{21,22}\) However, a large number of IncRNAs remain to be studied.

Previous studies on the non-coding genomes have developed objection against the original central dogma of molecular biology. Non-coding RNAs were demonstrated to be involved in the modulation of the expression of several genes, which suggested that they may influence the progression of tumors when they regulated tumor-related genes.\(^{23,24}\) LOXL1-AS1 was a newly discovered IncRNA first reported by Hauser et al.\(^{15}\) Subsequently, several studies reported its effects on prostate cancer and medulloblastoma. For example, Long et al.\(^{17}\) showed that LOXL1-AS1 expression was distinctly up-regulated in prostate cancer and its knockdown suppressed tumor cell proliferation via regulating miR-541-3p and CCND1. Gao et al.\(^{25}\) showed that LOXL1-AS1 was highly expressed and associated with advanced clinical stages in medulloblastoma patients, and its suppression inhibited tumor cells proliferation and metastasis by modulating the PI3K/AKT pathway. In recent years, circulating IncRNAs being used as novel biomarkers became a research hotspot, and several circulating IncRNAs have been confirmed to be associated with the clinical prognosis of tumor patients. Although the biological function of LOXL1-AS1 has been investigated in previous studies, its clinical significance has remained largely unclear.

In the present study, we first showed that circulating LOXL1-AS1 expression was distinctly up-regulated in EOC patients compared to healthy volunteers, and its higher expression was strongly correlated with advanced clinical stages, which suggested that the detection of circulating LOXL1-AS1 may have a diagnostic value. The results of ROC assays confirmed our hypothesis that detecting the levels of circulating LOXL1-AS1 can be used to distinguish low-grade patients from healthy individuals. Then, we divided all patients into two groups to explore its clinical significance, finding that a high level of circulating LOXL1-AS1 was correlated with advanced FIGO stage and positively distant metastasis, suggesting that the overexpression of LOXL1-AS1 acted as a positive factor contributing to the clinical progression of this tumor. Moreover, the association between circulating LOXL1-AS1 and overall survival was analyzed using Kaplan–Meier assays, and the results showed that patients with higher levels of circulating LOXL1-AS1 may have a poorer overall survival. Based on

### TABLE 2  Univariate and multivariate survival analysis of influencing factors

| Variable                     | Univariate analysis | Multivariate analysis |
|------------------------------|---------------------|-----------------------|
|                              | HR  | 95% CI   | \( p \) | HR  | 95% CI   | \( p \) |
| Age                          | 1.572 | 0.624–2.441 | 0.221 | –   | –   | –   |
| Tumor size                   | 1.423 | 0.852–2.668 | 0.432 | –   | –   | –   |
| Ascites                      | 1.744 | 0.761–3.344 | 0.156 | –   | –   | –   |
| FIGO stage                   | 3.342 | 1.451–4.776 | 0.011 | 2.894 | 1.216–4.327 | 0.016 |
| Distant metastasis           | 3.542 | 1.538–5.446 | 0.003 | 3.125 | 1.233–4.852 | 0.008 |
| Circulating LOXL1-AS1 expression | 3.342 | 1.368–5.138 | 0.002 | 3.053 | 1.154–4.784 | 0.007 |
multivariate Cox analysis, high expression of circulating LOXL1-AS1 was confirmed to be an independent prognostic indicator for the survival of EOC patients, and the relative risk (95% CI) was 3.053 (1.154–4.784). Taken together, circulating LOXL1-AS1 could be used as a potential marker to screen high-risk patients with EOC who may achieve a poor clinical prognosis and thus require aggressive clinical treatment.

We determined that circulating LOXL1-AS1 expression is significantly up-regulated in EOC and is correlated with several clinical pathologies. Higher serum circulating LOXL1-AS1 levels could distinguish patients with EOC from healthy controls. Accordingly, this lncRNA can function as an ideal indicator with respect to the diagnosis and clinical outcome of EOC.

AUTHOR CONTRIBUTIONS

CNL designed and performed all of the experiments and analyzed the data. HYZ wrote the manuscript. All authors read and approved the final version of the manuscript submitted for publication.

CONFLICT OF INTEREST STATEMENT

The authors declare that they have no conflicts of interest.

DATA AVAILABILITY STATEMENT

All data and materials regarding the present study are available from the corresponding author.

ORCID

Hai-Yan Zhang DOI: https://orcid.org/0000-0002-3699-8672

REFERENCES

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
2. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64:252–271.
3. Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3–14.
4. Kaldawy A, Segev Y, Lavie O, Auslender R, Sopik V, Narod SA. Low-grade serous ovarian cancer: a review. Gynecol Oncol. 2016;143:433–438.
5. Yang WL, Lu Z, Bast RC Jr. The role of biomarkers in the management of epithelial ovarian cancer. Expert Rev Mol Diagn. 2017;17:577–591.
6. Nicolas FE. Role of ncRNAs in development, diagnosis and treatment of human cancer. Recent Pat Anticancer Drug Discov. 2017;12(2):128–135.
7. Jathar S, Kumar V, Srivastava J, Tripathi V. Technological developments in IncRNA biology. Adv Exp Med Biol. 2017;1008:283–323.
8. Mathy NW, Chen XM. Long non-coding RNAs (lncRNAs) and their transcriptional control of inflammatory responses. J Biol Chem. 2017;292:12375–12382.
9. Clark BS, Blackshaw S. Understanding the role of IncRNAs in nervous system development. Adv Exp Med Biol. 2017;1008:253–282.
10. Wu Z, Liu X, Liu L, et al. Regulation of IncRNA expression. Cell Mol Biol Lett. 2014;19:561–575.
11. Peng WX, Koiala P, Mo YY. LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 2017;36:5661–5667.
12. He R, Wu JX, Zhang Y, Che H, Yang L. LncRNA LINCO0628 overexpression inhibits the growth and invasion through regulating PI3K/Akt signaling pathway in osteosarcoma. Eur Rev Med Pharmacol Sci. 2018;22:5857–5866.
13. Wu DD, Chen X, Sun KK, Wang LL, Chen S, Zhao Y. Role of the IncRNA ABHD11-AS1 in the tumorigenesis and progression of epithelial ovarian cancer through targeted regulation of RhoC. Mol Cancer. 2017;16:138.
14. Chen S, Wu DD, Sang XB, et al. The IncRNA HULK functions as an oncogene by targeting ATG7 and ITGIB1 in epithelial ovarian carcinoma. Cell Death Dis. 2017;8:e3118.
15. Hauser MA, Aboobakar IF, Liu Y, et al. Genetic variants and cellular stressors associated with exfoliation syndrome modulator promoter activity of a IncRNA within the LOXL1 locus. Hum Mol Genet. 2015;24:6552–6563.
16. Wang H, Li L, Yin L. Silencing LncRNA LOXL1-AS1 attenuates mesenchymal characteristics of glioblastoma via NF-kappaB pathway. Biochem Biophys Res Commun. 2018;500:518–524.
17. Long B, Li N, Xu XX, et al. Long noncoding RNA LOXL1-AS1 regulates prostate cancer cell proliferation and cell cycle progression through miR-541-3p and CCND1. Biochem Biophys Res Commun. 2018;505:561–568.
18. Bottoni P, Scatena R. The role of CA 125 as tumor marker: biochemical and clinical aspects. Adv Exp Med Biol. 2015;867:229–244.
19. Chen X, Zhang J, Zhang Z, Li H, Cheng W, Liu J. Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma. Hum Pathol. 2013;44:2373–2384.
20. Wang Y, Li Y, Song HQ, Sun GW. Long non-coding RNA LINCO0899 as a novel serum biomarker for diagnosis and prognosis prediction of acute myeloid leukemia. Eur Rev Med Pharmacol Sci. 2018;22:7364–7370.
21. Gong W, Tian M, Qiu H, Yang Z. Elevated serum level of IncRNA-H1F1A-AS1 as a novel diagnostic predictor for worse prognosis in colorectal carcinoma. Canc Biomarkers: Sec Dis Markers. 2017;20:417–424.
22. He B, Zeng J, Chao W, et al. Serum long non-coding RNAs MALAT1, AFAP1-AS1 and AL359062 AS diagnostic and prognostic biomarkers for nasopharyngeal carcinoma. Oncotarget. 2017;8:41166–41177.
23. Bartha I, di Iulio J, Venter JC, Telenti A. Human gene essentiality. Adv Exp Med Biol. 2017;1008:253–282.
24. Sherstyuk VV, Medvedev SP, Zakian SM. Noncoding RNAs in the regulating the PI3K/AKT pathway. Anal Cell Pathol (Amst). 2018;2018:9275685.

How to cite this article: Liu C-N, Zhang H-Y. Serum IncRNA LOXL1-AS1 is a diagnostic and prognostic marker for epithelial ovarian cancer. J Gene Med. 2020;22:e3233. https://doi.org/10.1002/jgm.3233